盐酸瑞芬太尼(Remifentanil Hydrochloride) - 药物靶点：μ opioid receptor_在研适应症：疼痛，麻醉_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Afentanil、Aruchiba、Remifentanil

+ [16]

靶点

μ opioid receptor

作用机制

μ opioid receptor激动剂(μ-阿片受体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

GSK PlcAspen Pharmacare Holdings Ltd.Abbott Laboratories (Philippines), Inc.

+ [4]

非在研机构

Air Liquide Santé (International) SA

最高研发阶段批准上市

首次获批日期

美国 (1996-07-12),

麻醉

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

结构

分子式C20H29ClN2O5

InChIKeyWFBMIPUMYUHANP-UHFFFAOYSA-N

CAS号132539-07-2

关联

850

项与盐酸瑞芬太尼相关的临床试验

NCT01003028 / Not yet recruiting临床4期IIT

Reduction of Remifentanil-related Complications by Limiting Maximum Plasma Concentration During Target-controlled Infusion

This study is intended to evaluate the effect of decreasing the maximum plasma concentration target of remifentanil of the Target Controlled Infusion system on the the incidence of major and minor side-effects.

开始日期2024-11-01

申办/合作机构

Seoul National University Hospital

NCT06205719 / Not yet recruiting早期临床1期IIT

Effect of Remazolam on Anesthesia Recovery in Patients Undergoing Fundus Surgery-A Single-center, Prospective, Randomized, Double-blind, Controlled Clinical Trial

to investigate the effect of remazolam benzenesulfonate in patients with ocular fundus surgery, so as to guide clinical anesthesiologists to choose more appropriate anesthetic drugs in fundus surgery

开始日期2024-06-01

申办/合作机构

四川省人民医院

NCT06454292 / Not yet recruiting临床4期IIT

Efficacy and Safety Study of Oliceridine Fumarate Versus Remifentanil for Analgesic Therapy in Mechanically Ventilated Subjects in the ICU

The objective of this clinical trial is to investigate the efficacy and safety of oliceridine fumarate for analgesic treatment in mechanically ventilated subjects in the ICU. This study was conducted to answer the following questions (1) the efficacy of oliceridine fumarate for analgesic treatment in subjects with ICU mechanical ventilation (2) the safety of oliceridine fumarate for analgesic treatment in subjects with ICU mechanical ventilation. This study proposes to conduct a randomized controlled clinical trial in mechanically ventilated patients in the intensive care unit to compare the analgesic efficacy and incidence of adverse effects of two drugs, oliceridine fumarate injection and remifentanil. Subjects had an analgesic goal of CPOT <3 points and a sedation goal of RASS -2 to 0 points. Infusion syringes of remifentanil or oliceridine fumarate were prepared by a nurse according to the weight of the subjects. Subjects were enrolled in the group and were scored for analgesia and sedation related scores. Both groups received routine ICU monitoring and appropriate treatment, which was determined by the clinician.

开始日期2024-06-01

申办/合作机构

四川省人民医院

100 项与盐酸瑞芬太尼相关的临床结果

登录后查看更多信息

100 项与盐酸瑞芬太尼相关的转化医学

登录后查看更多信息

100 项与盐酸瑞芬太尼相关的专利（医药）

登录后查看更多信息

6,035

项与盐酸瑞芬太尼相关的文献（医药）

2024-05-01·Current drug safety

Remimazolam and Remifentanil Use Induced Severe Respiratory Depression and Laryngeal Spasm During Intravenous Sedation and Analgesia: A Case Report

作者: Wang, Ning ; Wang, Huaizhou ; Xin, Zhijun

Introduction::

Intravenous sedation and analgesia are widely used in minor surgeries. Remifentanil and remimazolam are advantageous in this setting because of their rapid onset of action, and short duration of action leading to a rapid recovery. However, the two drugs combined need to be titrated to avoid airway-related adverse events.

Case Presentation::

This article reports a case of severe respiratory depression and severe laryngeal spasm induced by remifentanil and remimazolam when they were used for analgesia and sedation in a patient undergoing oral biopsy.

Conclusion::

We aim to improve awareness about the safety of these drugs among anesthesiologists and increase their ability to manage the risk associated with their use.

2024-04-01·Anaesthesia

The association between epidural labour analgesia and postpartum depression: a randomised controlled trial

Article

作者: Sng, B L ; Rahman, N ; Sultana, R ; Tan, H S ; Tan, C W ; Chen, H Y ; Sia, A T H ; Gandhi, M ; Chua, T

Summary:

There is conflicting evidence regarding the association between epidural labour analgesia and risk of postpartum depression. Most previous studies were observational trials with limited ability to account for confounders. We aimed to determine if epidural analgesia was associated with a significant change in the incidence of postpartum depression in this randomised controlled trial. We enrolled women aged 21–50 years old with a singleton fetus ≥ 36 weeks gestation. Patients were advised regarding available labour analgesic modalities during enrolment (epidural block; intramuscular pethidine; nitrous oxide; or intravenous remifentanil). On request for analgesia, patients were offered the modality that they had been allocated randomly to first. Blinded investigators recorded patient and obstetric characteristics within 24 h of delivery and assessed for postpartum depression at 6–10 weeks following delivery using the Edinburgh Postnatal Depression Scale (score ≥ 13 considered positive for postpartum depression). The modified intention‐to‐treat population consisted of all patients who received any form of labour analgesia, while per‐protocol consisted of patients who received their randomised modality as their first form of labour analgesia. Of 881 parturients allocated randomly (epidural n = 441, non‐epidural n = 440), we analysed 773 (epidural n = 389, non‐epidural n = 384); 62 (15.9%) of women allocated to epidural group developed postpartum depression compared with 65 (16.9%) women allocate to the non‐epidural group. There were no significant differences in the incidence of postpartum depression between the two groups (adjusted risk difference (95%CI) 1.6 (‐3.0–6.3%), p = 0.49). Similar results were obtained with per‐protocol analysis (adjusted risk difference (95%CI) ‐1.0 (‐8.3–6.3%), p = 0.79). We found no significant difference in the risk of postpartum depression between patients who received epidural labour analgesia and those who utilised non‐epidural analgesic modalities.

2024-04-01·Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses

Postoperative Pain Management in Coronary Artery Bypass Grafting: An Integrative Review

Review

作者: Dos Santos Felix, Márcia M ; da Silva Pires, Patrícia ; Calegari, Isadora B ; Raponi, Maria B G ; Barichello, Elizabeth ; Bertolini, Bruna ; de Andrade, Érica V ; Barbosa, Maria H

PURPOSE:

To identify pharmacological and nonpharmacological interventions adopted for pain relief in the postoperative period of coronary artery bypass graft surgery.

DESIGN:

Integrative review.

METHODS:

Studies published in English, Spanish, and Portuguese from January 2010 to December 2019 in Cumulative Index to Nursing and Allied Health Literature (CINAHL), Latin American and Caribbean Literature on Health Science, PubMed, and Web of Science. Two hundred studies were identified and eleven were included. Methodological analysis was performed using the Medical Education Research Study Quality Instrument.

FINDINGS:

The studies found were organized into three thematic categories: pharmacological interventions (methadone, morphine, lidocaine gel, remifentanil, sufentanil, and nefopam), nonpharmacological interventions (low-level laser therapy, light-emitting diode, Class IV laser, and transcutaneous nerve stimulation) and anesthetic techniques (dexmedetomidine, ultrasound-guided pectoral nerve block, high thoracic epidural analgesia, and perioperative parasternal block with levobupivacaine).

CONCLUSIONS:

A greater tendency to use drug strategies for postoperative pain relief was identified. The drugs used demonstrated efficacy and safety in the treatment of pain, with the exception of nefopam, which showed little benefit in this population. Nonpharmacological interventions, used as adjuvants to drug treatment, were shown to be safe, effective, and well tolerated by the patients.

62

项与盐酸瑞芬太尼相关的新闻（医药）

2024-06-26

·PRNewswire

Medasense Announces a Strategic Agreement With Global Medical Company, Nihon Kohden Corporation

RAMAT GAN, Israel, June 26, 2024 /PRNewswire/ -- Medasense, a global leader in pain monitoring solutions, is proud to announce a strategic partnership with Nihon Kohden for the exclusive distribution of its revolutionary pain monitoring device in Japan. This partnership is intended to transform pain management practices across Japanese healthcare facilities, offering a significant advancement in patient care. Nihon Kohden, renowned for its history of excellence in providing innovative high quality, reliable medical technology that improves the way healthcare is practiced, is partnering with Medasense to introduce its nociception monitor to the Japanese market. This cutting-edge device, with its state-of-the-art AI powered NOL - Nociception Level Index®, provides real-time, objective pain monitoring, enabling the personalization and optimization of pain treatment. It will be accessible to hospitals and clinics throughout Japan through Nihon Kohden's extensive distribution channels pending regulatory approval. Medasense's CEO & Founder, Galit Zuckerman, expressed enthusiasm about the collaboration: "We are honored to partner with Nihon Kohden, a company with a long history of excellence, that shares our vision of improving patient care through innovative solutions. Our mission is to help all patients suffer less from pain and the adverse effects of pain medication. Nihon Kohden's established clinical, technological leadership and expertise in the Japanese market make them the perfect partner to distribute our nociception monitor." NOL monitoring provides an AI powered, clinically validated index to objectively quantify the physiological response to pain (nociception) supporting clinicians in delivering personalized anesthesia tailored to patient requirements. With over 40 peer reviewed publications, clinical studies have demonstrated that NOL-guided analgesia resulted in intraoperative opioid sparing, and improved post operative pain scores and patient recovery.1,2 For more information about Medasense and Nihon Kohden, please visit and . About Medasense and NOL – Nociception Level Index® Technology Medasense is transforming pain management with its breakthrough technology that empowers clinicians to optimize and personalize pain control, significantly reducing the risk of pain or of overmedication. The company's flagship product, the PMD-200™, equipped with the NOL-Nociception Level Index®, leverages advanced artificial intelligence and a proprietary non-invasive sensor system. This unique platform provides objective monitoring and quantification of a patient's pain response, making it an essential tool in an operating room and critical care unit settings where patients cannot communicate their pain levels. The PMD-200 is the first and only monitor to be authorized by the FDA for pain measurement for anaesthesiology. It has been used in over 100,000 surgeries worldwide, and is commercially available in the US, Europe, Canada, Latin America and Israel. Watch Medasense's 1-minute video About Nihon Ko hden Founded in 1951, Nihon Kohden is a global leader of medical solutions with the goal to improve healthcare with advanced technology. For more than 70 years, Nihon Kohden has continued to provide a wide range of medical electronic equipment including EEG, EMG/EP measuring systems, electrocardiographs, bedside monitors, defibrillators, AEDs, ventilators, and hematology instruments. Nihon Kohden utilizes cutting-edge technology to support medical treatment in all clinical areas, integrating medical devices into the IT network to meet customers' requirements and offers a wide, comprehensive solution. For further information please contact: Rachel Weissbrod, VP Clinical & Market Development, Medasense +972-54-544-9115 [email protected] 1. Meijer, F., Honing, M., Roor, T., Toet, S., Calis, P., Olofsen, E., Martini, C., van Velzen, M., Aarts, L., Niesters, M., Boon, M., Dahan, A. (2020). Reduced postoperative pain using Nociception Level-guided fentanyl dosing during sevoflurane anaesthesia: a randomised controlled trial. British Journal of Anaesthesia, In Press. DOI: 2. Fleur S. Meijer, Chris H. Martini, Suzanne Broens, Martijn Boon, Marieke Niesters, Leon Aarts, Erik Olofsen, Monique van Velzen, Albert Dahan. Nociception-guided versus Standard Care during Remifentanil–Propofol Anesthesia: A Randomized Controlled Trial. Anesthesiology (2019); 130:745–755 Logo:

2024-06-22

·药时代

5400亿注射剂市场迎变局，超50款产品有望纳入第十批国采

正文共： 1680字 16图预计阅读时间： 5分钟据中康开思系统显示，注射剂在2023年全国等级医院市场规模超5400亿元，其中化学药占据主要份额。自2020年国家药监局推进化药注射剂仿制药一致性评价以来，2021年的第五批国家集采开始，化药注射液的占比明显增加，五年间已有超120个化药注射剂被纳入。 2023市场规模超3528亿 7大品种销售额破历史新高数据显示，2023年化药注射剂在全国等级医院的销售额达3528.77亿元，同比下滑0.2%。在化药注射剂的细分品类中，系统用抗感染药、血液和造血器官、神经系统占据前三的市场份额，分别达21.06%、19.68%、14.55%。化药注射剂全国等级医院销售情况来源：中康开思系统在2023年全国等级医院化药注射剂的销售额TOP10排行榜中，所有药物销售额均破30亿元，其中刷新往年销售记录的产品就多达7款。如氯化钠已连续7年超110亿元，2023年更破新高位居榜首，约143亿元。化药注射剂 2023全国等级医院销售额TOP10 来源：中康开思系统，新康界整理头孢哌酮舒巴坦首次突破80亿元，位居第二；哌拉西林钠他唑巴坦钠已连续3年位居榜三，2023年也首次拿下了超73亿元的成绩。此外，亮丙瑞林、丁苯酞、瑞芬太尼、异甘草酸镁等产品也在2023年刷新了自身近7年的销售额，分别达51亿元、45亿元、45亿元、33亿元。从销售增速来看，在销售额TOP10排行榜中，地佐辛、紫杉醇两款产品下滑明显，分别为-26.4%、-27.7%，其余7款产品均实现正向增长。其中，4款产品涨逾10%，瑞芬太尼表现亮眼，大涨34.1%；异甘草酸镁、葡萄糖、氯化钠分别上涨21.8%、20.4%、19.8%。值得注意的是，此次排名第16的美罗培南是第七批国家集采品种，该品种曾是年销售额近70亿的品种，且连续几年在全国等级医院化药注射剂的销售额TOP10排行榜中，名列前三。但自纳入集采后，2023年该品种急剧下滑55.4%，销售额跌至29.36亿元，2024年第一季度仅达7.33亿元。美罗培南全国等级医院销售情况来源：中康开思系统超50款产品有望纳入国采自2018年年末4+7城市试点开始，化药注射剂的国采备受市场瞩目，随着越来越多产品过评/视同过评，化药注射剂从第五批国采开始进入爆发期，五年间已有超120个产品被纳入集采名单。截至目前，还有超50个化药注射剂（按产品名统计）的竞争企业（原研+过评）≥5家，储备量十分充足。从企业来看，齐鲁制药、科伦药业、倍特药业、扬子江药业、石药控股分别都有超10款10+亿产品有望纳入第十批国采。齐鲁制药包括多柔比星、艾司洛尔等；科伦药业包括氨苄西林钠和头孢他啶等；倍特药业包括碘氟醇、氨苄西林钠等；石药控股包括多柔比星、氨苄西林钠等。部分已满足第十批国采品种来源：中康开思系统，新康界整理头孢类药物一直都是集采的重点药品之一，除第六批胰岛素专项集采外，每批国采都有头孢类药物，从第五批开始纳入注射剂，目前头孢类大品种基本都已经进入了国家集采。而尚未纳入第十批国采且竞争格局≥5家的头孢类品种已达7款，包括注射用拉氧头孢钠、注射用头孢他啶阿维巴坦钠和注射用头孢哌酮钠等。其中，拉氧头孢早前被纳入《2021年新疆等2+N联盟药品带量采购》、《湖南省2019年公立医疗机构抗菌药物专项集中采购》，但尚未被纳入国家集采，目前拉氧头孢已满足国采基本门槛，若后续被纳入，其市场格局将面临洗牌。由于现在全国价格联动，四同治理，某些地方集采的最低价可能会成为其他省份最高价的参考值，不少药企为抢占有利市场位置，地方集采时往往会提前采取优先降价的策略。如此前福建省药品集采中，浙江智达的盐酸多柔比星脂质体1580元独家中选，降幅高达64%。这些品种的国采条件已经成熟，早晚也得大降价，所以有药企选择提前大降价，也在情理之中。封面图来源：123rf 基因疗法的胜利计算赋能的PROTAC开发平台及License-out项目介绍 | 药时代路演第7期 AKT抑制剂，再传噩耗！小分子药物开发技术之酶的固定化及其应用 | 博腾·药时代直播间点击这里，原来很多老外朋友也在这里！

一致性评价带量采购

2024-06-21

·赛柏蓝

化药注射剂销售额Top10（附名单）

编者按：本文来自新康界，作者慧玲；赛柏蓝授权转载，编辑凯西注射剂在2023年全国等级医院市场规模超5400亿元，其中化学药占据主要份额。自2020年国家药监局推进化药注射剂仿制药一致性评价以来，2021年的第五批国家集采开始，化药注射液的占比明显增加，五年间已有超120个化药注射剂被纳入。 01 2023市场规模超3528亿 7大品种销售额破历史新高数据显示，2023年化药注射剂在全国等级医院的销售额达3528.77亿元，同比下滑0.2%。在化药注射剂的细分品类中，系统用抗感染药、血液和造血器官、神经系统占据前三的市场份额，分别达21.06%、19.68%、14.55%。化药注射剂全国等级医院销售情况在2023年全国等级医院化药注射剂的销售额TOP10排行榜中，所有药物销售额均破30亿元，其中刷新往年销售记录的产品就多达7款。如氯化钠已连续7年超110亿元，2023年更破新高位居榜首，约143亿元。 02 化药注射剂 2023全国等级医院销售额TOP10 头孢哌酮舒巴坦首次突破80亿元，位居第二；哌拉西林钠他唑巴坦钠已连续3年位居榜三，2023年也首次拿下了超73亿元的成绩。此外，亮丙瑞林、丁苯酞、瑞芬太尼、异甘草酸镁等产品也在2023年刷新了自身近7年的销售额，分别达51亿元、45亿元、45亿元、33亿元。从销售增速来看，在销售额TOP10排行榜中，地佐辛、紫杉醇两款产品下滑明显，分别为-26.4%、-27.7%，其余7款产品均实现正向增长。其中，4款产品涨逾10%，瑞芬太尼表现亮眼，大涨34.1%；异甘草酸镁、葡萄糖、氯化钠分别上涨21.8%、20.4%、19.8%。值得注意的是，此次排名第16的美罗培南是第七批国家集采品种，该品种曾是年销售额近70亿的品种，且连续几年在全国等级医院化药注射剂的销售额TOP10排行榜中，名列前三。但自纳入集采后，2023年该品种急剧下滑55.4%，销售额跌至29.36亿元，2024年第一季度仅达7.33亿元。美罗培南全国等级医院销售情况 03 超50款产品有望纳入国采自2018年年末4+7城市试点开始，化药注射剂的国采备受市场瞩目，随着越来越多产品过评/视同过评，化药注射剂从第五批国采开始进入爆发期，五年间已有超120个产品被纳入集采名单。截至目前，还有超50个化药注射剂（按产品名统计）的竞争企业（原研+过评）≥5家，储备量十分充足。从企业来看，齐鲁制药、科伦药业、倍特药业、扬子江药业、石药控股分别都有超10款10+亿产品有望纳入第十批国采。齐鲁制药包括多柔比星、艾司洛尔等；科伦药业包括氨苄西林钠和头孢他啶等；倍特药业包括碘氟醇、氨苄西林钠等；石药控股包括多柔比星、氨苄西林钠等。部分已满足第十批国采品种头孢类药物一直都是集采的重点药品之一，除第六批胰岛素专项集采外，每批国采都有头孢类药物，从第五批开始纳入注射剂，目前头孢类大品种基本都已经进入了国家集采。而尚未纳入第十批国采且竞争格局≥5家的头孢类品种已达7款，包括注射用拉氧头孢钠、注射用头孢他啶阿维巴坦钠和注射用头孢哌酮钠等。其中，拉氧头孢早前被纳入《2021年新疆等2+N联盟药品带量采购》、《湖南省2019年公立医疗机构抗菌药物专项集中采购》，但尚未被纳入国家集采，目前拉氧头孢已满足国采基本门槛，若后续被纳入，其市场格局将面临洗牌。由于现在全国价格联动，四同治理，某些地方集采的最低价可能会成为其他省份最高价的参考值，不少药企为抢占有利市场位置，地方集采时往往会提前采取优先降价的策略。如此前福建省药品集采中，浙江智达的盐酸多柔比星脂质体1580元独家中选，降幅高达64%。这些品种的国采条件已经成熟，早晚也得大降价，所以有药企选择提前大降价，也在情理之中。 END 内容沟通：郑瑶（13810174402）医药代表交流群扫描下方二维码加入银发经济市场机遇交流群扫描下方二维码加入左下角「关注账号」，右下角「在看」，防止失联

一致性评价

100 项与盐酸瑞芬太尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01177	盐酸瑞芬太尼	N01AH06	DB00899

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
疼痛	瑞士	GSK Plc	1997-01-28
麻醉	美国	Mylan Institutional LLC	1996-07-12

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
镇痛	临床3期	德国	GSK Plc	2006-11-01
镇静	临床3期	德国	GSK Plc	2006-11-01
痛觉过敏	临床1期	德国	Air Liquide Santé (International) SA	2012-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02631135 (CTgov)	临床4期	-	40	Propofol+Rocuronium+Remifentanil (Group 1 (TIVA))	遞膚艱積製壓構壓構窪(鹽窪蓋淵鬱觸鏇簾齋醖) = 壓簾鹹衊餘遞齋鹹獵鏇齋膚鑰鹽憲鹹鏇鹽餘鏇 (餘鏇鹹憲繭築獵積範窪, 夢膚壓壓艱顧艱壓鹽鏇 ~ 蓋襯鏇鏇製構範壓膚艱) 更多	-	2024-05-17
				Dexmedetomidine+Propofol+Rocuronium+Remifentanil (Group 2 (TIVA+D))	遞膚艱積製壓構壓構窪(鹽窪蓋淵鬱觸鏇簾齋醖) = 廠憲夢願艱觸繭製膚鹹齋膚鑰鹽憲鹹鏇鹽餘鏇 (餘鏇鹹憲繭築獵積範窪, 襯鹽選築觸廠選襯積廠 ~ 齋繭壓蓋鏇夢淵鑰壓構) 更多
NCT03207100 (Pubmed)	N/A	脑出血	338	Intervention group (remifentanil and dexmedetomidine)	網製憲構廠壓鏇鹽積壓(觸憲獵窪窪淵夢觸繭夢) = 鏇淵餘繭構餘夢範鬱選鬱範製構鑰糧遞窪廠窪 (願製選淵衊構鏇繭醖夢 )	-	2024-03-27
				remifentanil	網製憲構廠壓鏇鹽積壓(觸憲獵窪窪淵夢觸繭夢) = 齋製選艱構範壓繭膚遞鬱範製構鑰糧遞窪廠窪 (願製選淵衊構鏇繭醖夢 )
NCT03643796 (CTgov)	临床4期	椎间盘疾病	32	Remifentanil (Remifentanil Group)	遞醖選廠膚齋膚鹽憲醖(觸願壓鹽壓鏇鹽夢範鑰) = 憲膚淵鑰襯鹹遞鏇網願淵糧衊醖鹹鹽襯窪獵襯 (淵鹹鏇築鬱選選壓繭齋, 夢壓窪廠顧鏇觸製積襯 ~ 製製鹹範醖窪膚膚醖範) 更多	-	2023-09-18
				Dexmedetomidine+Ketamine (Ketamine and Dexmedetomidine Group)	遞醖選廠膚齋膚鹽憲醖(觸願壓鹽壓鏇鹽夢範鑰) = 襯齋蓋繭願積壓餘積壓淵糧衊醖鹹鹽襯窪獵襯 (淵鹹鏇築鬱選選壓繭齋, 繭壓鬱夢遞積積鹹顧廠 ~ 遞鬱壓製網淵築鏇鹽齋) 更多
ChiCTR2100054565 (Pubmed)	临床4期	-	-	Remifentanil	膚鹽範鏇遞獵糧蓋鏇積(獵築製廠積醖觸餘壓淵) = which occurred in 3 patients 簾艱選築憲壓膚鑰膚夢 (壓餘鹽淵積壓觸艱淵簾 )	-	2023-06-28
NCT02989597 (CTgov)	临床4期	术后疼痛	10	Spinal Fusion Surgery+Sufentanil+Methadone Hydrochloride+Dexamethasone+ketamine+Remifentanil (Intra-operative Methadone Hydrochloride)	壓膚餘選願鏇獵簾憲簾(積鬱觸構襯繭獵廠廠蓋) = 糧鹽膚範餘醖憲淵蓋願製壓衊遞範願簾蓋築鹹 (憲遞築繭齋鑰糧築膚鹹, 遞遞構鑰艱顧蓋窪鑰願 ~ 顧顧觸顧艱窪窪蓋壓艱) 更多	-	2023-04-25
				Spinal Fusion Surgery+Sufentanil+Dexamethasone+ketamine+Remifentanil (Control)	壓膚餘選願鏇獵簾憲簾(積鬱觸構襯繭獵廠廠蓋) = 網構築蓋網構鏇網築鹽製壓衊遞範願簾蓋築鹹 (憲遞築繭齋鑰糧築膚鹹, 餘齋繭醖壓艱鹽壓夢壓 ~ 範鹽鑰願膚觸廠蓋範遞) 更多
NCT03283150 (CTgov)	临床4期	镇静	20	Remifentanil (Remifentanil)	網蓋範簾夢顧製廠衊鏇(積選壓壓齋膚鏇糧簾鑰) = 壓憲艱構醖選獵構觸簾膚簾鬱壓構衊鹹憲蓋衊 (蓋鹹膚繭簾齋餘顧願餘, 鏇餘糧襯窪鏇壓膚簾鑰 ~ 網鏇淵襯鹽窪膚鏇衊築) 更多	-	2023-03-27
				Propofol (Propofol)	蓋範醖積鏇餘襯憲構淵(簾願簾顧襯憲積顧獵鏇) = 願膚顧鏇蓋艱鏇築鬱襯鹹鑰網獵鹹鹽窪鬱簾積 (製憲網壓構簾鏇衊鏇遞, 蓋獵鹽膚簾窪憲願鹹範 ~ 鬱糧壓繭鏇範夢網艱簾) 更多
NCT05217238 (Pubmed)	N/A	疼痛	-	Remifentanil (Group R1)	鬱窪鬱鏇鹹鑰積遞淵積(構衊壓夢顧鹹醖襯膚醖) = 構窪襯窪夢衊鬱獵鏇窪衊鏇願範衊齋齋餘淵壓 (選顧製膚襯膚鹽願鏇糧, 1.186 ~ 1.351)	-	2023-03-08
				Remifentanil (Group R2)	鬱窪鬱鏇鹹鑰積遞淵積(構衊壓夢顧鹹醖襯膚醖) = 廠選醖簾醖繭膚醖鹽膚衊鏇願範衊齋齋餘淵壓 (選顧製膚襯膚鹽願鏇糧, 1.065 ~ 1.324)
NCT03960801 (Pubmed)	临床3期	-	1,150	Neuromuscular blockers	夢簾獵齋簾繭淵衊製壓(窪壓網壓願衊鬱衊鹽襯) = 鬱鹽夢積醖選願鏇製製廠蓋積構顧選繭壓廠願 (夢網鏇獵鑰範網鹽蓋選 )	-	2023-01-03
				Remifentanil	夢簾獵齋簾繭淵衊製壓(窪壓網壓願衊鬱衊鹽襯) = 淵窪鏇壓膚蓋鬱積鹽鑰廠蓋積構顧選繭壓廠願 (夢網鏇獵鑰範網鹽蓋選 )
Pubmed \| Curr Pharm Des	N/A	咳嗽 \| 麻醉	-	Ramosetron 0.3 mg	餘夢範廠鹹鬱憲醖鹹範(範糧糧憲壓鏇淵艱廠壓) = 蓋窪鹹簾膚壓艱鏇憲襯鑰淵憲淵膚膚顧窪襯願 (構選簾簾範鏇廠淵簾憲 ) 更多	-	2022-04-12
				Normal saline	餘夢範廠鹹鬱憲醖鹹範(範糧糧憲壓鏇淵艱廠壓) = 壓糧簾糧夢膚觸蓋顧觸鑰淵憲淵膚膚顧窪襯願 (構選簾簾範鏇廠淵簾憲 ) 更多
NCT03996148 (CTgov)	临床4期	颈动脉狭窄	21	Propofol+Desflurane+Remifentanil (Remifentanil, Propofol, and Desflurane)	蓋製選簾醖窪網鑰壓觸(廠餘窪遞壓顧艱願蓋窪) = 築窪網醖鹹積廠網廠醖網網鹽遞衊製淵遞築鑰 (憲選衊範鹽壓繭製遞淵, 選製膚廠網簾蓋鏇齋範 ~ 選顧積餘積獵壓夢願壓) 更多	-	2022-04-06
				Dexmedetomidine+Desflurane+Remifentanil (Remifentanil, Dexmedetomidine, and Desflurane)	蓋製選簾醖窪網鑰壓觸(廠餘窪遞壓顧艱願蓋窪) = 鹽鹽餘簾淵鹽憲選餘醖網網鹽遞衊製淵遞築鑰 (憲選衊範鹽壓繭製遞淵, 糧糧製憲襯鏇窪網糧襯 ~ 製廠醖夢繭獵鹹積簾鑰) 更多